Property of Idaho State Police Forensic Services Uncontrolled
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
MDPV Bath Salts Test
One Step Methylenedioxypyrovalerone Drug of Abuse Test MATERIALS Analytical Sensitivity The cut-off concentration of the One Step Methylenedioxypyrovalerone Drug of Abuse Test is determined to be 1,000ng/mL. (Dip Card) Materials Provided: Test was run in 30 replicates with negative urine and standard control at ±25% cut-off and ±50% cut-off concentration levels. Test results ● Dip cards are summarized below. For Forensic Use Only ● Desiccants ● Package insert Test Result INTENDED USE Percent of Cut-off n Materials Required But Not Provided: Methylenedioxypyrovalerone Concentration in ng/mL The One Step Methylenedioxypyrovalerone Drug of Abuse Test is a lateral flow chromatographic immunoassay for the ● Specimen collection container Negative Positive qualitative detection of Methylenedioxypyrovalerone (MDPV) in human urine specimen at the cut-off level of 1,000ng/mL. This ● Disposable gloves 0% Cut-off assay is intended for forensic use only. ● Timer 30 30 0 This assay provides only a preliminary qualitative test result. A more specific confirmatory reference method, such as Liquid (No Drug Present) chromatogra -50% Cut-off phy tandem mass spectrometry (LC/MS/MS) or gas chromatography/mass spectrometry (GC/MS) must be use in INSTRUCTIONS FOR USE] 30 30 0 order to obtain a confirmed analytical result. (500ng/mL) 1) Remove the dip card from the foil pouch. -25% Cut-off 30 30 0 BACKGROUND 2) Remove the cap from the dip card. Label the device with patient or control identifications. (750ng/mL) 3) Immerse the absorbent tip into the urine sample for 5 seconds. Urine sample should not touch the plastic device. Cut-off ‘Bath salts’, a form of designer drugs, also promoted as ‘plant food’ or ‘research chemicals’, is sold mainly in head shops, on 4) Replace the cap over the absorbent tip and lay the dip card on a clean, flat, and non-absorptive surface. -
PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 Mg/Ml Β2-Adrenergic Stimulant Bronchodilator AA P
PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulphate Syrup House Standard 2 mg/mL 2-Adrenergic Stimulant Bronchodilator AA PHARMA INC. DATE OF PREPARATION: 1165 Creditstone Road, Unit #1 April 10, 2014 Vaughan, Ontario L4K 4N7 Control Number: 172362 1 PRODUCT MONOGRAPH ORCIPRENALINE Orciprenaline Sulfate Syrup House Standard 2 mg/mL THERAPEUTIC CLASSIFICATION 2–Adrenergic Stimulant Bronchodilator ACTIONS AND CLINICAL PHARMACOLOGY Orciprenaline sulphate is a bronchodilating agent. The bronchospasm associated with various pulmonary diseases - chronic bronchitis, pulmonary emphysema, bronchial asthma, silicosis, tuberculosis, sarcoidosis and carcinoma of the lung, has been successfully reversed by therapy with orciprenaline sulphate. Orciprenaline sulphate has the following major characteristics: 1) Pharmacologically, the action of orciprenaline sulphate is one of beta stimulation. Receptor sites in the bronchi and bronchioles are more sensitive to the drug than those in the heart and blood vessels, so that the ratio of bronchodilating to cardiovascular effects is favourable. Consequently, it is usually possible clinically to produce good bronchodilation at dosage levels which are unlikely to cause cardiovascular side effects. 2 2) The efficacy of the bronchodilator after both oral and inhalation administration has been demonstrated by pulmonary function studies (spirometry, and by measurement of airways resistance by body plethysmography). 3) Rapid onset of action follows administration of orciprenaline sulphate inhalants, and the effect is usually noted immediately. Following oral administration, the effect is usually noted within 30 minutes. 4) The peak effect of bronchodilator activity following orciprenaline sulphate generally occurs within 60 to 90 minutes, and this activity lasts for 3 to 6 hours. 5) Orciprenaline sulphate taken orally potentiates the action of a bronchodilator inhalant administered 90 minutes later, whereas no additive effect occurs when the drugs are given in reverse order. -
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. -
Psilocybin Mushrooms Fact Sheet
Psilocybin Mushrooms Fact Sheet January 2017 What are psilocybin, or “magic,” mushrooms? For the next two decades thousands of doses of psilocybin were administered in clinical experiments. Psilocybin is the main ingredient found in several types Psychiatrists, scientists and mental health of psychoactive mushrooms, making it perhaps the professionals considered psychedelics like psilocybin i best-known naturally-occurring psychedelic drug. to be promising treatments as an aid to therapy for a Although psilocybin is considered active at doses broad range of psychiatric diagnoses, including around 3-4 mg, a common dose used in clinical alcoholism, schizophrenia, autism spectrum disorders, ii,iii,iv research settings ranges from 14-30 mg. Its obsessive-compulsive disorder, and depression.xiii effects on the brain are attributed to its active Many more people were also introduced to psilocybin metabolite, psilocin. Psilocybin is most commonly mushrooms and other psychedelics as part of various found in wild or homegrown mushrooms and sold religious or spiritual practices, for mental and either fresh or dried. The most popular species of emotional exploration, or to enhance wellness and psilocybin mushrooms is Psilocybe cubensis, which is creativity.xiv usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with Despite this long history and ongoing research into its v a common dose around 1-2.5 grams. therapeutic and medical benefits,xv since 1970 psilocybin and psilocin have been listed in Schedule I of the Controlled Substances Act, the most heavily Scientists and mental health professionals criminalized category for drugs considered to have a consider psychedelics like psilocybin to be “high potential for abuse” and no currently accepted promising treatments as an aid to therapy for a medical use – though when it comes to psilocybin broad range of psychiatric diagnoses. -
Near the Himalayas, from Kashmir to Sikkim, at Altitudes the Catholic Inquisition, and the Traditional Use of These of up to 2700 Meters
Year of edition: 2018 Authors of the text: Marc Aixalà & José Carlos Bouso Edition: Alex Verdaguer | Genís Oña | Kiko Castellanos Illustrations: Alba Teixidor EU Project: New Approaches in Harm Reduction Policies and Practices (NAHRPP) Special thanks to collaborators Alejandro Ponce (in Peyote report) and Eduardo Carchedi (in Kambó report). TECHNICAL REPORT ON PSYCHOACTIVE ETHNOBOTANICALS Volumes I - II - III ICEERS International Center for Ethnobotanical Education Research and Service INDEX SALVIA DIVINORUM 7 AMANITA MUSCARIA 13 DATURA STRAMONIUM 19 KRATOM 23 PEYOTE 29 BUFO ALVARIUS 37 PSILOCYBIN MUSHROOMS 43 IPOMOEA VIOLACEA 51 AYAHUASCA 57 IBOGA 67 KAMBÓ 73 SAN PEDRO 79 6 SALVIA DIVINORUM SALVIA DIVINORUM The effects of the Hierba Pastora have been used by Mazatec Indians since ancient times to treat diseases and for divinatory purposes. The psychoactive compound Salvia divinorum contains, Salvinorin A, is the most potent naturally occurring psychoactive substance known. BASIC INFO Ska Pastora has been used in divination and healing Salvia divinorum is a perennial plant native to the Maza- rituals, similar to psilocybin mushrooms. Maria Sabina tec areas of the Sierra Madre Oriental Mountains of Mexi- told Wasson and Hofmann (the discoverers of its Mazatec co. Its habitat is tropical forests, where it grows between usage) that Salvia divinorum was used in times when the- 300 and 800 meters above sea level. It belongs to the re was a shortage of mushrooms. Some sources that have Lamiaceae family, and is mainly reproduced by cuttings done later feldwork point out that the use of S. divinorum since it rarely produces seeds. may be more widespread than originally believed, even in times when mushrooms were abundant. -
Temporary Class Drug Order Report: 5-6APB and Nbome Compounds
ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0555 [email protected] Home Secretary Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 29 May 2013 Dear Home Secretary, I am writing to formally request that you consider laying a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on the following two groups of novel psychoactive substances (NPS). We consider the laying of TCDOs is appropriate as a pre-emptive measure in advance of the summer music festival season. Both classes of drugs have been associated with serious harm and drug-related deaths. ‘Benzofury’ compounds 5- and 6-APB and related substances are phenethylamine-type materials, related to ecstasy (MDMA). There have been several deaths and hospitalisations in the UK associated with these NPS, although poly-substance use often complicates the case. Research indicates that there is a potential risk of cardiac toxicity associated with the long-term use of 5- and 6-APB. Anecdotal user reports suggest that the consumption of these substances can cause insomnia, increased heart rate and anxiety, with some users reporting MDMA like symptoms. The related compound 5-IT has been subject to an EMCDDA-Europol joint report and an EMCDDA risk assessment exercise. [www.emcdda.europa.eu/publications/joint-reports/5- IT] 1 The substances recommended for control are: 5- and 6-APB: (1-(benzofuran-5-yl)-propan-2-amine and 1-(benzofuran-6-yl)-propan- 2-amine) and their N-methyl derivatives. -
Ring-Substituted Amphetamine Interactions with Neurotransmitter Receptor Binding Sites in Human Cortex
208 NeuroscienceLetters, 95 (1988) 208-212 Elsevier Scientific Publishers Ireland Ltd. NSL O5736 Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex Pamela A. Pierce and Stephen J. Peroutka Deparmentsof Neurologyand Pharmacology, Stanford University Medical Center, StanJbrd,CA 94305 (U.S.A.) (Received 31 May 1988; Revised version received 11 August 1988; Accepted 12 August 1988) Key words.' Ring-substituted amphetamine; (_+)-3,4-Methylenedioxyamphetamine; ( +_)-3,4-Methylene- dioxyethamphetamine; (_+)-3,4-Methylenedioxymethamphetamine; Ecstasy; 4-Bromo-2,5- dimethoxyphenylisopropylamine binding site; Human cortical receptor The binding affinities of 3 ring-substituted amphetamine compounds were determined at 9 neurotrans- mitter binding sites in human cortex. (_+)-3,4-Methylenedioxyamphetamine (MDAk (_+)-3,4-methylene- dioxyethamphetamine (MDE), and (_+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') all display highest affinity (approximately 1 /tM) for the recently identified 'DOB binding site' labeled by ['TBr]R(-)4-bromo-2,5-dimethoxyphenylisopropylamine ([77Br]R(-)DOB). MDA displays moderate affinity (4-5/iM) for the 5-hydroxytryptaminetA (5-HTr^), 5-HT_D,and =,-adrenergic sites in human cor- tex. MDE and MDMA display lower affinity or are inactive at all other sites tested in the present study. These observations are discussed in relation to the novel psychoactive effects of the ring-substituted amphetamines. A series of ring-substituted amphetamine derivatives exist which are structurally related to both amphetamines and hallucinogens. However, drugs such as (+)-3,4- methylenedioxyamphetamine (MDA), (_+)-3,4-methylenedioxyethamphetamine (MDE), and (+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') ap- pear to produce unique psychoactive effects which are distinct from the effects of both amphetamines and hallucinogens [13, 15]. -
The Place of Physical Exercise and Bronchodilator Drugs in the Assessment of the Asthmatic Child
Arch Dis Child: first published as 10.1136/adc.38.202.539 on 1 December 1963. Downloaded from Arch. Dis. Childh., 1963, 38, 539. THE PLACE OF PHYSICAL EXERCISE AND BRONCHODILATOR DRUGS IN THE ASSESSMENT OF THE ASTHMATIC CHILD BY R. S. JONES, M. J. WHARTON and M. H. BUSTON From Alder Hey Children's Hospital and the Department of Child Health, University ofLiverpool (RECEIVED FOR PUBLICATION MAY 9, 1963) Among the many factors that affect ventilatory exercise. Isoprenaline sulphate I % (Burroughs Wellcome function in the asthmatic subject, physical exercise preparation) was given as an aerosol using a Wright and bronchodilator drugs are two of the more inhaler and an air flow rate of 8-9 litres per minute important. It has been shown that physical exercise (Wright, 1958). The aerosol was fed into a face mask has two distinct and opposite effects on ventilatory held close to the face. The substance was inhaled for one minute and for two subsequent half-minute periods function depending upon the duration and level of during a total time of five minutes. Solutions of exercise (Jones, Buston and Wharton, 1962). adrenaline and noradrenaline were made up from the Providing the level is adequate, exercise lasting less solid substances (Burroughs Wellcome preparations) in than two minutes increases the forced expiratory strengths of 1% with added sodium metabisulphite. volume in one second (F.E.V.), whereas exercise These preparations were used fresh and were inhaled by copyright. lasting eight to 10 minutes produces a fall of F.E.V. in the same way as isoprenaline. -
The Entheogen Review , Pob 19820, Sa Cramento , Ca 95819-0820, Usa 161 Vol Ume X, Number 4 Winter Solstice 2001
VOL UME X, NUMBER 4 WINTER SOLSTICE 2001 Index Symbols Age of Entheogens & The Angels’ Dictionary, Analog Act 84, 85 The 154 Anand, Margot 67, 154 ∞Ayes 32, 49, 50, 51 age regression 89 Anderson, E.F. 106 1,4-butanediol 84 Aguaruna Indians 10 Anderson, Rocky 41 1984 155 Aguirre, G., L.E. 3, 5, 6 Anderson, Sherry 156 2001 52 Agurell, S. 57, 58, 106 Andrews, S. 86 2C-B 22, 28, 118 ahpí 7 anesthetize 21 2C-D 20 ajucá 6 angico 6 2C-I 20 Akashic record 54 angicos brancos 6 2C-T-2 20, 22, 90 Al-Queda terrorists 123 angicos pretos 6 2C-T-4 20 Alarcón, R. 5 angiquín 6 2C-T-7 20, 85, 89, 90, 94, 105, 114 Alchemind Society, The 42, 76, 112 angiquinho 6 4-acetoxy-DET 88, 89, 90, 92, 93, 96 alcohol Angraecum fragrans 86 4-acetoxy-DIPT 29, 30, 88, 90, 91, 93 38, 52, 74, 84, 98, 99, 134, 145, 146 Anon. 151 4-hydroxy-αMT 139 alcoholic beverages 86 anonymous remailer 123 4-hydroxy-DET 88, 89, 139 Aldrich 83 anthraquinones 86 4-hydroxy-DMT 88 alfalfa 129 anti-cholinergic-like central effect 150 4-hydroxy-DPT 139 alien 32, 50, 53 anti-depressant 28 5-MeO-αMT 148 alien robots 52 anti-inflammatory 86 5-MeO-DIPT 90, 94 AllChemical Arts (conference) 115 anti-marijuana laws 46 5-MeO-DMT Allen, John W. 112 anti-nausea medications 28 1, 5, 25, 84, 89, 99, 101, 102, 103, allergy preparations 28 antibacterial 135 118, 126, 148 Alli, Antero 114 antibiotic 28 5-methoxytryptamine 150 Allison 156 antidiarrheal 104 Alpert, Richard 34 antispasmatic 28 A alpha 140, 141, 142, 143, 144, 145 Antonil, André João 4 Aardvark, David α-MT 148 ants 151 α 21, 27, 28, 30, 34, 51, -
Differentially Affect Monoamine Transporters and Abuse Liability
Neuropsychopharmacology (2017) 42, 1950–1961 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability Ernesto Solis Jr1, John S Partilla2, Farhana Sakloth3, Iwona Ruchala4, Kathryn L Schwienteck5, 4 4 3 5 *,2 Louis J De Felice , Jose M Eltit , Richard A Glennon , S Stevens Negus and Michael H Baumann 1In Vivo Electrophysiology Unit, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, 3 National Institutes of Health, Baltimore, MD, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; 4 5 Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Clandestine chemists synthesize novel stimulant drugs by exploiting structural templates known to target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respectively). 4-Methylamphetamine (4-MA) is an emerging drug of – abuse that interacts with transporters, but limited structure activity data are available for its analogs. Here we employed uptake and release assays in rat brain synaptosomes, voltage-clamp current measurements in cells expressing transporters, and calcium flux assays in cells coexpressing transporters and calcium channels to study the effects of increasing N-alkyl chain length of 4-MA on interactions at DAT, NET, and SERT. In addition, we performed intracranial self-stimulation in rats to understand how the chemical modifications affect abuse liability. -
MDMA, MBDB' and I! I the Classichallucinogens
Differences Between the Mechanism I t of Action of MDMA, MBDB' and i! I the ClassicHallucinogens. i Identification of a New Therapeutic Class: Entactogens Jawi'ri", ! 7 U$ DAVID E. NICHOLS, PH.D.* The widespread use of psychedelic drugs, such as quantitative structure-activity relationships (QSARs). lysergic ac;.d diethylamide (LSD), during the 1960's and Simply stated, attempts are made to find quantitative 1970's IcC to severe reactions by governmental agencies correlations (or equations) that relate biological activity to and proscriptions against their use. However, with the fundamental properties of the molecule. This approach is high deg _e of interest in mind-altering drugs in the being widely developed in the pharmaceutical industry in United States, as evidenced by their widespread popular- order to understand more fully how particular types of ity, it wasonlyamatteroftimebeforenewdrugsappeared drugs work, and to be able to predict which additional that were developed outside of the pharmaceutical corn- molecules should be synthesized. It should also be added panics, that no equations have been developed that adequately j Nearly 70 years after its first synthesis, 3,4- correlate hallucinogenic or psychedelic activity with any methy'enedioxymethamphetamine (MDMA) was redis- particular molecular property. covered. Although it had its' more recent origin in the class In this context, it is important to define clearly the of dr. gs that is generally defined as psychedelic or hallu- type of biological activity that is being measured. It is cino enic, it clearly appears different from LSD. In hu- typical that if a molecule has several different sites of mar , MDMA induces a state of reduced anxiety and action in the brain, that each oneof these actions may be lc .red defensiveness that makes it attractive to thera- related to entirely different structural features or proper- pi . -
Recommended Methods for the Identification and Analysis Of
Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.